Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Operating expenses:
Research and development	$ 9,135	$ 7,655	$ 18,031	$ 12,171
General and administrative	3,449	2,790	6,931	5,476
Total operating expenses	12,584	10,445	24,962	17,647
Loss from operations	(12,584)	(10,445)	(24,962)	(17,647)
Total other income (expense), net	163	53	387	100
Consolidated net loss	(12,421)	(10,392)	(24,575)	(17,547)
Net loss attributable to noncontrolling interest in Pangu BioPharma Limited	1	1	2	5
Net loss attributable to aTyr Pharma, Inc.	$ (12,420)	$ (10,391)	$ (24,573)	$ (17,542)
Net loss per share, basic	$ (0.44)	$ (0.64)	$ (0.88)	$ (1.16)
Net loss per share, diluted	$ (0.44)	$ (0.64)	$ (0.88)	$ (1.16)
Shares used in computing net loss per share, basic	28,063,387	16,128,473	27,941,560	15,121,721
Shares used in computing net loss per share, diluted	28,063,387	16,128,473	27,941,560	15,121,721